Cargando…

Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT

Differentiated thyroid cancer (DTC) represents the most common thyroid cancer histotype. Generally, it exhibits a good prognosis after conventional treatments; nevertheless, about 20% of patients can develop a local recurrence and/or distant metastasis. In one-third of advanced DTC, the metastatic l...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrari, Cristina, Santo, Giulia, Ruta, Rossella, Lavelli, Valentina, Rubini, Dino, Mammucci, Paolo, Sardaro, Angela, Rubini, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392185/
https://www.ncbi.nlm.nih.gov/pubmed/34441351
http://dx.doi.org/10.3390/diagnostics11081417
_version_ 1783743441805508608
author Ferrari, Cristina
Santo, Giulia
Ruta, Rossella
Lavelli, Valentina
Rubini, Dino
Mammucci, Paolo
Sardaro, Angela
Rubini, Giuseppe
author_facet Ferrari, Cristina
Santo, Giulia
Ruta, Rossella
Lavelli, Valentina
Rubini, Dino
Mammucci, Paolo
Sardaro, Angela
Rubini, Giuseppe
author_sort Ferrari, Cristina
collection PubMed
description Differentiated thyroid cancer (DTC) represents the most common thyroid cancer histotype. Generally, it exhibits a good prognosis after conventional treatments; nevertheless, about 20% of patients can develop a local recurrence and/or distant metastasis. In one-third of advanced DTC, the metastatic lesions lose the ability to take up iodine and become radioactive iodine-refractory (RAI-R) DTC. In this set of patients, the possibility to perform localized treatments should always be taken into consideration before the initiation of systemic therapy. In the last decade, some multi-tyrosine kinase inhibitor (MKI) drugs were approved for advanced DTC, impacting on patient’s survival rate, but at the same time, these therapies have been associated with several adverse events. In this clinical context, the role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography ([(18)F]FDG PET/CT) in the early treatment response to these innovative therapies was investigated, in order to assess the potentiality of this diagnostic tool in the early recognition of non-responders, avoiding unnecessary therapy. Herein, we aimed to present a critical overview about the reliability of [(18)F]FDG PET/CT in the early predictive response to MKIs in advanced differentiated thyroid cancer.
format Online
Article
Text
id pubmed-8392185
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83921852021-08-28 Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT Ferrari, Cristina Santo, Giulia Ruta, Rossella Lavelli, Valentina Rubini, Dino Mammucci, Paolo Sardaro, Angela Rubini, Giuseppe Diagnostics (Basel) Review Differentiated thyroid cancer (DTC) represents the most common thyroid cancer histotype. Generally, it exhibits a good prognosis after conventional treatments; nevertheless, about 20% of patients can develop a local recurrence and/or distant metastasis. In one-third of advanced DTC, the metastatic lesions lose the ability to take up iodine and become radioactive iodine-refractory (RAI-R) DTC. In this set of patients, the possibility to perform localized treatments should always be taken into consideration before the initiation of systemic therapy. In the last decade, some multi-tyrosine kinase inhibitor (MKI) drugs were approved for advanced DTC, impacting on patient’s survival rate, but at the same time, these therapies have been associated with several adverse events. In this clinical context, the role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography ([(18)F]FDG PET/CT) in the early treatment response to these innovative therapies was investigated, in order to assess the potentiality of this diagnostic tool in the early recognition of non-responders, avoiding unnecessary therapy. Herein, we aimed to present a critical overview about the reliability of [(18)F]FDG PET/CT in the early predictive response to MKIs in advanced differentiated thyroid cancer. MDPI 2021-08-05 /pmc/articles/PMC8392185/ /pubmed/34441351 http://dx.doi.org/10.3390/diagnostics11081417 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ferrari, Cristina
Santo, Giulia
Ruta, Rossella
Lavelli, Valentina
Rubini, Dino
Mammucci, Paolo
Sardaro, Angela
Rubini, Giuseppe
Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT
title Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT
title_full Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT
title_fullStr Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT
title_full_unstemmed Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT
title_short Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT
title_sort early predictive response to multi-tyrosine kinase inhibitors in advanced refractory radioactive-iodine differentiated thyroid cancer: a new challenge for [(18)f]fdg pet/ct
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392185/
https://www.ncbi.nlm.nih.gov/pubmed/34441351
http://dx.doi.org/10.3390/diagnostics11081417
work_keys_str_mv AT ferraricristina earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct
AT santogiulia earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct
AT rutarossella earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct
AT lavellivalentina earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct
AT rubinidino earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct
AT mammuccipaolo earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct
AT sardaroangela earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct
AT rubinigiuseppe earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct